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TABLE 1 Acute Conditions Associated With New-Onset AF Among Hospitalized Adults
Acute Condition
Number With
New-Onset AF*
(Total N ¼ 22,780)
% New-Onset AF
With Condition*
% Condition
With New-Onset AF
Multivariate-Adjusted†
OR for New-Onset AF
(95% CI)
Noncardiac surgery (n ¼ 641,071) 8,481 37.2 1.3 3.08 (2.99–3.18)
Infection (n ¼ 730,379) 7,944 34.9 1.1 1.54 (1.49–1.59)
Cardiac surgery (n ¼ 23,083) 4,804 21.9 20.8 52.4 (50.2–54.7)
Myocardial infarction (n ¼ 77,848) 2,234 9.8 2.9 1.41 (1.34–1.48)
Pulmonary embolism (n ¼ 20,939) 244 1.1 1.2 1.43 (1.26–1.63)
Thyrotoxicosis (n ¼ 10,172) 141 0.6 1.4 1.78 (1.49–2.12)
Myocarditis or pericarditis (n ¼ 3,705) 126 0.6 3.4 1.73 (1.41–2.12)
*Individual patients may have multiple diagnoses associated with new-onset AF. †Model adjusted for age, race, sex, history of diabetes mellitus, hypertension, heart failure,
chronic pulmonary disease, stroke, metastatic cancer, prior myocardial infarction, and the acute conditions infection, surgery (cardiac and noncardiac), myocardial infarction,
alcohol intoxication, pulmonary embolism, thyrotoxicosis, and myocarditis or pericarditis.
AF ¼ atrial ﬁbrillation; CI ¼ conﬁdence interval; OR ¼ odds ratio.
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2433Our study was limited by the ability of ICD-9-CM
codes to identify temporal proximity between
acute diagnoses and AF, especially when multiple
diagnoses occurred simultaneously. Our results may
not be generalizable outside of hospitalized patients.
We were unable to identify whether AF present at the
time of admission was new or pre-existing, a limita-
tion that may result in underestimates of the associ-
ation between some acute conditions and new-onset
AF. Furthermore, cardiac rhythm monitoring may be
more likely in some clinical scenarios (e.g., after car-
diac surgery), and may have inﬂuenced our results.
In conclusion, we have examined risks for new-
onset AF associated with acute conditions in a
representative sample of hospitalized patients. Our
ﬁndings inform prior knowledge gaps regarding acute
conditions associated with new-onset AF and may
provide targets for improved processes of care.*Allan J. Walkey, MD, MSc
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Inappropriate and
Nonrecommended
Prasugrel Prescription
Great VariationsWe read with great interest the work by Hira et al. (1)
presenting a high rate of prasugrel prescription with
inappropriate or nonrecommended indications. In
previous studies, prasugrel was prescribed at hospital
discharge despite the presence of at least one con-
traindication in 9.6% of patients, while inappropriate
prasugrel prescription within 24 h of admission was
observed in 1.8% of patients (2,3). Differences in
provider type, data elements collected, and deﬁni-
tions applied may account for these variations, and
this should be highlighted.
No net clinical beneﬁt from prasugrel compared
with clopidogrel has been described, not only in the
subgroup of patients $75 years of age but also in those
with low body weight (<60 kg). Therefore, in the pra-
sugrel package insert, body weight < 60 kg is reported
as a risk factor for bleeding, constituting, in our view, a
nonrecommended indication. It would be interesting
to know the prevalence of patients weighing <60 kg in
the studied population, providing an estimate of how
many additional patients likely received prasugrel for
a nonrecommended indication. Additional risk factors
increasing the risk for bleeding are included in the
black-box warning and have been speciﬁcally reported
to affect nonrecommended selection of prasugrel (4).
Data on prasugrel’s use in patients receiving
concomitant aspirin and warfarin are extremely
important, and it would be very interesting to have
some idea about this subgroup’s outcomes. In a much
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2434smaller study of patients on similar triple therapy, an
increased bleeding risk was reported, raising partic-
ular concern for this combination in the medical
community (5). We strongly disagree with the
characterization of prasugrel on top of aspirin and
warfarin as nonrecommended only in patients
$75 years of age. According to prasugrel’s package
insert, concomitant use of medications that increase
the risk for bleeding is a risk factor for bleeding.
Therefore, a nonrecommended indication is more
appropriate for all patients taking prasugrel as part of
triple-antithrombotic therapy.*Dimitrios Alexopoulos, MD
Ioanna Xanthopoulou, MD
John Goudevenos, MD
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61:2060–6.REPLY: Frequency of Inappropriate and
Nonrecommended Prasugrel Prescription
Great VariationsWe appreciate the comments of Dr. Alexopoulos and
colleagues regarding our study on the frequency
and practice-level variation in inappropriate and
nonrecommended prasugrel prescribing from the
National Cardiovascular Data Registry PINNACLE
Registry (1).We did ﬁnd differences in provider and insurance
characteristics, with patients who were receiving
prasugrel inappropriately being less likely to have
seen physicians (89.5% vs. 93.8%; p < 0.001) and to
have private insurance (53.8% vs. 64.3%; p < 0.001)
compared with patients receiving prasugrel appro-
priately. The PINNACLE Registry uses standard deﬁ-
nitions for all practices, but data are self-reported.
Some practice-level variation could be explained by
reporting bias, but this could not be ascertained from
the registry. Furthermore, we did want to evaluate
the off-label use of prasugrel in patients without
histories of acute coronary syndromes or not under-
going percutaneous coronary intervention, but this
information could not be reliably extracted, as data
about myocardial infarction and percutaneous coro-
nary intervention were available for only 12 months
before a patient’s visit.
The prasugrel package insert (2) does mention
weight <60 kg as an additional risk factor for
bleeding but does not specify that it is not recom-
mended. The approved dose of prasugrel is 5 mg/day
in patients weighing #60 kg, compared with the
standard dose of 10 mg/day in those weighing
>60 kg. We agree that despite decreased platelet
reactivity, the dose of 5 mg/day in patients weighing
#60 kg has not been studied prospectively to
determine its effect on ischemic outcomes compared
with clopidogrel (3) and warrants caution. Of
24,112 patients in our study who were receiving
prasugrel and had weight data available, 911 (4.11%)
weighed <60 kg.
We found that 4,248 of our overall cohort of 27,533
patients (15.4%) were receiving “triple therapy” with
aspirin, warfarin, and prasugrel. Among them, 319
received prasugrel inappropriately (history of tran-
sient ischemic attack or stroke) and 677 for non-
recommended indications (age $ 75 years with no
history of diabetes or myocardial infarction) likely
increasing their bleeding risk. We would like to draw
attention to this and are not stating that triple ther-
apy is not recommended only in patients $75 years of
age. Furthermore, we welcome the suggestion of the
need for outcome studies in these patients, but the
PINNACLE Registry at the time of the publication of
this report did not collect data on ischemic and
bleeding outcomes.*Ravi S. Hira, MD
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